Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Emrullah Yilmaz, Nofisat Ismaila, Julie E. Bauman, Raetasha Dabney, Gregory Gan, Richard Jordan, Marnie Kaufman, Kedar Kirtane, Sean Matthew McBride, Matthew O. Old, Lisa Rooper, Nabil F. Saba, Siddharth Sheth, Rathan M. Subramaniam, Trisha Michel Wise-Draper, Deborah Wong, Loren K. Mell

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


PURPOSETo provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers.METHODSASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-Analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTSThe literature search identified 28 relevant studies to inform the evidence base for this guideline.RECOMMENDATIONSWhen possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence.Additional information is available at

Original languageEnglish (US)
Pages (from-to)1132-1146
Number of pages15
JournalJournal of Clinical Oncology
Issue number5
StatePublished - Feb 10 2023
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline'. Together they form a unique fingerprint.

Cite this